{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T04:01:58Z","timestamp":1750564918340,"version":"3.41.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1999,8,1]],"date-time":"1999-08-01T00:00:00Z","timestamp":933465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1999,8,1]],"date-time":"1999-08-01T00:00:00Z","timestamp":933465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[1999,8]]},"DOI":"10.1023\/a:1006263226099","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T01:20:41Z","timestamp":1040520041000},"page":"237-250","source":"Crossref","is-referenced-by-count":15,"title":["Cisplatin\u2013epirubicin\u2013paclitaxel weekly administration in advanced breast cancer: A phase I study of the Southern Italy Cooperative Oncology Group"],"prefix":"10.1007","volume":"56","author":[{"given":"Giuseppe","family":"Frasci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"D'Aiuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Comella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Apicella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Immacolata","family":"Capasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio Di","family":"Bonito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Carten\u00ec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Biglietto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi De","family":"Lucia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigii","family":"Maiorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Piccolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"D'Aniello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Lapenta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Comella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"233931_CR1","first-page":"1","volume":"330","author":"Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer: hormonal, cytotoxicimmunotherapy.","year":"1992","unstructured":"Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer: hormonal, cytotoxic and immunotherapy. Lancet 330: 1\u201315, 1992","journal-title":"Lancet"},{"key":"233931_CR2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/bjc.1993.146","volume":"67","author":"R A'Hern","year":"1993","unstructured":"A'Hern R, Smith I, Ebbs S: Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in cooper type regimens. Br J Cancer 67: 801\u2013805, 1993","journal-title":"Br J Cancer"},{"key":"233931_CR3","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.1996.14.8.2197","volume":"14","author":"PA Greenberg","year":"1996","unstructured":"Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14: 2197\u20132205, 1996","journal-title":"J Clin Oncol"},{"key":"233931_CR4","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/jnci\/83.24.1797-a","volume":"83","author":"FA Holmes","year":"1991","unstructured":"Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Budzar AU, Frye DK, Hortobagyi GN: Phase II trial of Taxol: an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797\u20131805, 1991","journal-title":"J Natl Cancer Inst"},{"key":"233931_CR5","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1200\/JCO.1995.13.5.1152","volume":"13","author":"AD Seidman","year":"1995","unstructured":"Seidman AD, Reichman BS, Crown JP, Yao TJ, Currie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P, Lepore J, Marks L, Fain K, Souhrada M, Onetto N, Arbuck S, Norton L: Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 13: 1152\u20131159, 1995","journal-title":"J Clin Oncol"},{"key":"233931_CR6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.1995.13.2.314","volume":"13","author":"B Chevallier","year":"1995","unstructured":"Chevallier B, Fumoleau P, Kerbrat P, Azli N, Bayssas M, Lentz MA, van Glabbeke M, Dieras V, Roche H, Krakowski I: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13: 314\u2013324, 1995","journal-title":"J Clin Oncol"},{"key":"233931_CR7","first-page":"112a","volume":"17","author":"W Sikov","year":"1998","unstructured":"Sikov W, Akerley W, Strenger R, Cummings F: Weekly highdose paclitaxel demonstrates significant activity in advanced breast cancer (Abstract). Proc Am Soc Clin Oncol 17: 112a, 1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"233931_CR8","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.1998.16.10.3353","volume":"16","author":"AD Seidman","year":"1998","unstructured":"Seidman AD, Hudis C, Albanel J, Tong W, Tepler I, Currie V, Moynahan M, Theodoulou M, Gollub M, Baselga J, Norton L: Dose-dense therapy with weekly 1-h paclitaxel infusion in the treatment of metastatic breast cancer. J Clin Oncol 16: 3353\u20133361, 1998","journal-title":"J Clin Oncol"},{"key":"233931_CR9","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1995.13.11.2688","volume":"13","author":"L Gianni","year":"1995","unstructured":"Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C, Stefanelli M, Valagussa P, Bonadonna G: Paclitaxel by 3-h infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688\u20132699, 1995","journal-title":"J Clin Oncol"},{"key":"233931_CR10","first-page":"109","volume":"15","author":"GL Frassineti","year":"1996","unstructured":"Frassineti GL, Zoli W, Tienghi A, Ravaioli A, Milandri C, Gentile A, Onetto N, Amadori D: Phase I\/II study of sequential combination of paclitaxel and doxorubicin in the treatment of advanced breast cancer (Abstract) Proc Am Soc Clin Oncol 15: 109, 1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"233931_CR11","first-page":"126","volume":"15","author":"G Schwartsmann","year":"1996","unstructured":"Schwartsmann G, Menke CH, Caleffi M, Xavier N, Ferreira Filho AF, Schunemann H, Koya R, Stroda PR, Pohlmann P, Vengas LF, Kalakun L: Phase II trial of taxol, doxorubicin plus G-CSF in patients with metastatic breast cancer (Abstract). Proc Am Soc Clin Oncol 15: 126, 1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"233931_CR12","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.1997.15.7.2510","volume":"15","author":"PF Conte","year":"1997","unstructured":"Conte PF, Baldini E, Gennari A, Salvadori B, Gennari A, Da Prato M, Tibaldi C, Salzano E, Gentile A: Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 h, a regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 15: 2510\u20132517, 1997","journal-title":"J Clin Oncol"},{"key":"233931_CR13","first-page":"1a","volume":"16","author":"CW Sledge","year":"1997","unstructured":"Sledge CW, Neuberg D, Ingle J, Martino S, Wood W: Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs doxorubicinpaclitaxel (A+T), as first-line therapy for metastatic breast cancer (MBC): an intergroup trial (Abstract). Proc Am Soc Clin Oncol 16: 1a, 1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"233931_CR14","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1200\/JCO.1988.6.12.1811","volume":"6","author":"GW Sledge","year":"1988","unstructured":"Sledge GW, Loehrer P3, Roth BK, Einhom LH: Cisplatin as first-line therapy for metastatic breast cancer: J Clin Oncol 6: 1811\u20131814, 1988","journal-title":"J Clin Oncol"},{"key":"233931_CR15","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/bjc.1992.169","volume":"65","author":"IF Smith","year":"1992","unstructured":"Smith IF, Talbot DC: Cisplatin and its analogues in the treatment of advanced breast cancer: a review. Br J Cancer 65: 787\u2013793, 1992","journal-title":"Br J Cancer"},{"key":"233931_CR16","first-page":"140","volume":"15","author":"L Dogliotti","year":"1996","unstructured":"Dogliotti L, Danese S, Berruti A, Zola P, Bottini A, Buniva T, Richiardi G, Moro G, Farrris A, Porcile G, Zaffaroni N: Epirubicin, cisplatin and lonidarnine in advanced breast cancer: a phase II study (Abstract). Proc Am Soc Clin Oncol 15: 140, 1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"233931_CR17","first-page":"3856","volume":"45","author":"SN Roy","year":"1985","unstructured":"Roy SN, Horwitz SB: A phosphoglycoprotein associated with with Taxol-resistance in J774.2 cells. Cancer Res 45: 3856\u20133863, 1985","journal-title":"Cancer Res"},{"key":"233931_CR18","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1172\/JCI115080","volume":"87","author":"RJ Parker","year":"1991","unstructured":"Parker RJ, Eastman A, Bostick-Bruton F, Reed E: Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 87: 772\u2013777, 1991","journal-title":"J Clin Invest"},{"key":"233931_CR19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1005945218155","volume":"49","author":"G Frasci","year":"1998","unstructured":"Frasci G, Comella P, D'Aiuto G, Budillon A, Barbarulo D, Thomas R, Capasso I, Casaretti R, Daponte A, Caponigro F, Gravina A, Carteni' G, Gentile A, Comella G: Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer: a phase II study. Breast Cancer Res Treat 49: 13\u201326, 1998","journal-title":"Breast Cancer Res Treat"},{"key":"233931_CR20","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1200\/JCO.1996.14.4.1185","volume":"14","author":"KA Gelmon","year":"1996","unstructured":"Gelmon KA, O'Reilly SE, Tolcher AW, Zola P, Bottini A, Buniva T, Richiardi G, Moro G, Farrris A, Porcile G, Zaffaroni N: Phase I\/II study of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 14: 1185\u20131191, 1996","journal-title":"J Clin Oncol"},{"key":"233931_CR21","first-page":"120","volume":"15","author":"W McCaskill-Stevens","year":"1996","unstructured":"McCaskill-Stevens W, Ansari R, Fisher W, Penningion K, Dobbs C, Gonin R, Schaefer S, Loesch D, Sledge G: Phase II study of biweekly cisplatin and paclitaxel in the treatment of metastatic breast cancer (Abstract). Proc Am Soc Clin Oncol 15: 120, 1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"233931_CR22","first-page":"114","volume":"15","author":"JA Sparano","year":"1996","unstructured":"Sparano JA, Neuberg D, Glick JH, Robert NJ, Goldstein LJ, Sledge GW, Wood W: A phase II trial of biweekly paclitaxel and cisplatin in patients with advanced breast carcinoma: an Eastern Cooperative Oncology Group trial (Abstract). Proc Am Soc Clin Oncol 15: 114, 1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"233931_CR23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M: Reporting results of cancer treatment. Cancer 47: 207\u2013214, 1981","journal-title":"Cancer"},{"key":"233931_CR24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"ES Kaplan","year":"1958","unstructured":"Kaplan ES, Meier P: Non parametric estimation for incomplete observations. J Am Stat Assoc 53: 557\u2013580, 1958","journal-title":"J Am Stat Assoc"},{"key":"233931_CR25","first-page":"481a","volume":"17","author":"G Frasci","year":"1998","unstructured":"Frasci G, Comella P, Panza N, Pacilio C, Nicolella GP, Natale M, Manzione L, Gravina A, Cioffi R, Maiorino L, Comella G: Cisplatin-gemcitabine-paclitaxel in advanced non-small cell lung cancer: A dose-finding study (Abstract 1850). Proc Am Soc Clin Oncol 17: 481a, 1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"233931_CR26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.1995.13.1.180","volume":"13","author":"L Gianni","year":"1995","unstructured":"Gianni L, Kearns C, Giani A, Capri G, Vigano L, Locatelli A, Bonadonna G, Egorin MJ: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic\/ pharmacodynamic relationships in humans. J Clin Oncol 13: 180\u2013190, 1995","journal-title":"J Clin Oncol"},{"key":"233931_CR27","first-page":"373a","volume":"16","author":"A Lissoni","year":"1997","unstructured":"Lissoni A, Sessa C, Gabriele A, Bonazzi C, Pittelli MR, Marzola M, Mangioni C: Cisplatin, epirubicin and paclitaxel in uterine adenocarcinoma (Abstract). Proc. Am Soc Clin Oncol 16: 373a, 1997","journal-title":"Proc. Am Soc Clin Oncol"},{"key":"233931_CR28","first-page":"369a","volume":"16","author":"MA Dimopoulos","year":"1997","unstructured":"Dimopoulos MA, Papadimitriou CA, Akrivos T, Vlahos G, Georgoulias N, Voulgaris Z, Diacomanolis E, Papadimitris C, Athanassiades P, Mihalas S: Paclitaxel, cisplatin and epirubicin with G-CSF for newly diagnosed patients with epithelial ovarian cancer (Abstract). Proc Am Soc Clin Oncol 16: 369a, 1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"233931_CR29","first-page":"374a","volume":"16","author":"RW Naumann","year":"1997","unstructured":"Naumann RW, Alvarez RD, Omura GA, Segars ET, Roland PY, Kilgore LC, Partridge EE: A phase I study of paclitaxel and cisplatin with escalating doses of doxorubicin in patients with previously untreated epithelial ovarian cancer (Abstract). Proc Am Soc Clin Oncol 16: 374a, 1997","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl17","key":"233931_CR30","first-page":"35","volume":"24","author":"HJ Luck","year":"1997","unstructured":"Luck HJ, Thomssen C, du Bois A, Untch M, Lisboa B, Kohler G, Diergarten K: Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer. Semin Oncol 24 (Suppl 17): 35\u201339, 1997","journal-title":"Semin Oncol"},{"issue":"Suppl17","key":"233931_CR31","first-page":"40","volume":"24","author":"U Kohler","year":"1997","unstructured":"Kohler U, Olbricht SS, Fuechsel G, Kettner E, Richter B, Ridwelski K: Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer. Results of a clinical phase II study. Semin Oncol 24 (Suppl 17): 40\u201343, 1997","journal-title":"Semin Oncol"},{"key":"233931_CR32","first-page":"178a","volume":"16","author":"R Lalisang","year":"1997","unstructured":"Lalisang R, Nortier J, Wils J, Erdkamp F, Wals J, Hillen H, Blijiam G: Dose dense epirubicin and paclitaxel with G-CSF in metastatic breast cancer: a weekly schedule? (Abstract). Proc Am Soc Clin Oncol 16: 178a, 1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"233931_CR33","first-page":"355a","volume":"17","author":"MEL van der Burgh","year":"1998","unstructured":"van der Burgh MEL, de Wit R, Stoter G, Verweij J: Phase I study of weekly cisplatin and weekly or 4-weekly taxol: a highly active regimen in advanced epithelial ovarian cancer (Abstract). Proc Am Soc Clin Oncol 17: 355a, 1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"233931_CR34","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","volume":"15","author":"B Fisher","year":"1997","unstructured":"Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB, Fisher ER, Wickerman DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483\u20132494, 1997","journal-title":"J Clin Oncol"},{"issue":"Suppl17","key":"233931_CR35","first-page":"10","volume":"24","author":"A Moliterni","year":"1997","unstructured":"Moliterni A, Tarenzi E, Capri G, Terenziani M, Bertuzzi A, Grasselli G, Agresti R, Piotti P, Greco M, Salvadori B, Pilotti S, Lombardi F, Valagussa P, Bonadonna G, Gianni L: Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer. Semin Oncol 24 (Suppl 17): 10\u201314, 1997","journal-title":"Semin Oncol"},{"key":"233931_CR36","first-page":"165a","volume":"17","author":"EA Perez","year":"1998","unstructured":"Perez EA, Suman VJ, Krook JE, Stella PJ, Hartmann LC, Hat-field AK, Fitch T, Ingle JN: Phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast cancer: a North Central Cancer Treatment Group trial (Abstract). Proc Am Soc Clin Oncol 17: 165a, 1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"233931_CR37","first-page":"139a","volume":"17","author":"LG Estevez","year":"1998","unstructured":"Estevez LG, Andrade J, Robles L, Casado V, Ageitos AG, Domine M, Vicente J, Lobo F: Taxol-cisplatinum in patients with breast cancer previously treated with an anthracycline containing regimen (Abstract 530). Proc Am Soc Clin Oncol17: 139a, 1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"233931_CR38","first-page":"139a","volume":"17","author":"A Ezzat","year":"1998","unstructured":"Ezzat A, Rahal M, Raja MA, Raginwala M, Bazarbashi S: Pathologic response to paclitaxel-cisplatin versus fluorouracildoxorubicin-cyclophosphamide primary chemotherapy in locally advanced breast cancer (Abstract). Proc Am Soc Clin Oncol 17: 139a, 1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"233931_CR39","first-page":"174a","volume":"17","author":"C Sola","year":"1998","unstructured":"Sola C, Lluch A, Garcia-Conde J, Ojeda B, Hornedo J, Benavides M, Solano C, Garcia T, Salazar R, Alonso S, Cortes-Funes H, Lopez JJ: Phase II study of weekly paclitaxel in recurrent breast cancer after high-dose chemotherapy (Abstract). Proc Am Soc Clin Oncol 17: 174a, 1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"233931_CR40","first-page":"l88a","volume":"17","author":"A Alvarez","year":"1998","unstructured":"Alvarez A, Mickiewicz E, Brosio C, Giglio R, Cinat G, Suarez A: Weekly taxol in patients who had relapsed or remained stable with taxol in a 21 day schedule (Abstract). Proc Am Soc Clin Oncol 17: l88a, 1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"233931_CR41","first-page":"111a","volume":"17","author":"T Gamucci","year":"1998","unstructured":"Gamucci T, Piccart M, Bruning P, Klijn J, Biganzoli L, Houston S, Coleman R, Van Vreckem A, Cleall S, Curran D, Awada A, Paridaens R: Single agent taxol versus doxorubicin as firstline chemotherapy in advanced breast cancer. Final results of an EORTC randomized study with crossover (Abstract). Proc Am Soc Clin Oncol 17: 111a, 1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"233931_CR42","first-page":"101a","volume":"17","author":"E Winer","year":"1998","unstructured":"Winer E, Berry D, Duggan D, Henderson IC, Cirrincione C, Cooper R, Norton L: Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer. Results from CALGB 9342 (Abstract). Proc Am Soc Clin Oncol 17: 101a, 1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"233931_CR43","first-page":"110a","volume":"17","author":"FA Holmes","year":"1998","unstructured":"Holmes FA, Valero V, Budzar AU, Booser DJ, Winn R, Tolcker A, Seidman A, Goodwin W, Bearden I, Baysinger L, Hortobagyi GN, Arbuck SA: Final results: randomized phase III trial of paclitaxel by 3-h versus 96-h infusion in patients with breast cancer. The long and short of it (Abstract). Proc Am Soc Clin Oncol 17: 110a, 1998","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1006263226099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1006263226099\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1023\/A:1006263226099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1006263226099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:25:45Z","timestamp":1750479945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1006263226099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,8]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1999,8]]}},"alternative-id":["233931"],"URL":"https:\/\/doi.org\/10.1023\/a:1006263226099","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[1999,8]]}}}